Journal
FUTURE MEDICINAL CHEMISTRY
Volume 8, Issue 3, Pages 287-295Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc.15.191
Keywords
amyotrophic lateral sclerosis; CNS distribution; multiple sclerosis; neurological disorders; Parkinson's disease; pharmacokinetic profile; S1R agonist
Categories
Ask authors/readers for more resources
Aim: Nowadays, there is a great interest in the therapeutic potential of sigma1 receptor ligands for treating different CNS pathologies. Our previous investigations led to identify (R)-RC-33 as a potent and selective S1R agonist. Results: Herein, we report the gram-scale synthesis, pharmacokinetic profile and CNS distribution of (R)-RC-33 in the mouse to determine the most suitable dosage schedule for in vivo administration. For comparative purposes, the same experiments were also performed with PRE-084, the most widely used S1R agonist commonly in pharmacological experiments. Discussion: (R)-RC-33 shows a similar pharmacokinetic profile and a better CNS distribution when compared with PRE-084. Conclusion: (R)-RC-33 may be a promising candidate for in vivo studies in animal models of neurodegenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available